We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Phosphorylated-Tau Blood Test Identifies Asymptomatic Alzheimer’s Disease

By LabMedica International staff writers
Posted on 10 Aug 2020
Print article
Abnormal accumulation of tau protein in neuronal cell bodies (arrow) and neuronal extensions (arrowhead) in the neocortex of a patient who had died with Alzheimer\'s disease (Photo courtesy of Wikimedia Commons)
Abnormal accumulation of tau protein in neuronal cell bodies (arrow) and neuronal extensions (arrowhead) in the neocortex of a patient who had died with Alzheimer\'s disease (Photo courtesy of Wikimedia Commons)
A blood test that determines circulating levels of the Alzheimer's disease (AD) biomarker protein phospho-tau217 (p-tau217) was found to distinguish AD from other neurodegenerative diseases, with significantly higher accuracy than established plasma- and MRI-based biomarkers, and its performance was not significantly different from key cerebral spinal fluid (CSF)- or PET-based measurements.

The tau proteins are a group of six highly soluble protein isoforms produced by alternative splicing from the MAPT (microtubule-associated protein tau) gene. They have roles primarily in maintaining the stability of microtubules in axons and are abundant in the neurons of the central nervous system (CNS). They are less common elsewhere but are also expressed at very low levels in CNS astrocytes and oligodendrocytes. Pathologies and dementias of the nervous system such as Alzheimer's disease and Parkinson's disease are associated with tau proteins that have morphed into hyperphosphorylated insoluble aggregates called neurofibrillary tangles.

In the current study, investigators at Lund University (Sweden) and their collaborators sought to determine the discriminative accuracy of plasma p-tau217 for differentiating Alzheimer’s disease from other neurodegenerative disorders and neuropathologically defined AD from non-AD individuals.

For this study, the investigators worked with a new p-tau217 blood test, developed by Eli Lilly and Company (Indianapolis, IN, USA;), to analyze samples from 1,402 cognitively impaired and unimpaired research participants from studies in Arizona (Cohort 1: 81 Arizona participants in Banner Sun Health Research Institute's Brain Donation program), Sweden (Cohort 2: 699 participants in the Swedish BioFINDER Study), and Colombia (Cohort 3: 522 autosomal dominant Alzheimer's disease (ADAD)-causing mutation carriers and non-carriers).

The accuracy of plasma p-tau217 was compared with other key plasma, CSF, PET, and MRI biomarkers for AD. Secondary objectives were to investigate the age at which plasma p-tau217 levels increased in autosomal-dominant AD and if plasma p-tau217 levels were associated with AD-like tau pathology, determined using neuropathology or tau-PET.

Results revealed that in Cohort 1, plasma p-tau217 differentiated neuropathologically defined AD from non-AD with significantly higher accuracy than plasma p-tau181 and neurofilament light chain (NfL). The discriminative accuracy of plasma p-tau217 in Cohort 2 for clinical AD dementia versus other neurodegenerative diseases was significantly higher than plasma p-tau181, plasma NfL, and MRI measures but not significantly different compared with CSF p-tau217, CSF p-tau181, and tau-PET. In Cohort 3, plasma p-tau217 levels were significantly greater among PSEN1 mutation carriers, compared with noncarriers, from approximately 25 years and older, which is 20 years prior to estimated onset of MCI (mild cognitive impairment) among mutation carriers.

Plasma p-tau217 levels correlated with tau tangles in participants with but not without beta-amyloid plaques in Cohort 1. In Cohort 2, plasma p-tau217 discriminated abnormal versus normal tau-PET scans with significantly higher accuracy than plasma p-tau181, plasma NfL, CSF p-tau181, CSF beta-amyloid 42/beta-amyloid 40 ratio, and MRI measures, but its performance was not significantly different compared with CSF p-tau217.

"The p-tau217 blood test has great promise in the diagnosis, early detection, and study of Alzheimer's," said senior author Dr. Oskar Hansson, professor of clinical memory research at Lund University. "While more work is needed to optimize the assay and test it in other people before it becomes available in the clinic, the blood test might become especially useful to improve the recognition, diagnosis, and care of people in the primary care setting."

The study was published in the July 28, 2020, online edition of the Journal of the American Medical Association.

Related Links:


Lund University
Eli Lilly and Company
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.